SEC Filings Reveal: What Novo and Lilly Told Investors About 2026 Pricing
Novo and Lilly's 2025 SEC filings reveal what the companies actually expect from 2026 GLP-1 pricing, Medicare exposure, and competitive dynamics. Pulled directly from the 10-K and 20-F.
Public companies talk to two audiences: the press releases and the SEC filings. Press releases control narrative; SEC filings control liability. For GLP-1 market intelligence in 2026, the SEC filings from Novo Nordisk and Eli Lilly are the single most reliable source of what the companies actually expect to happen on pricing, volume, and competitive position.
This source check pulls directly from the companies' 2025 annual reports, Q4 2025 earnings transcripts, and material disclosures filed in early 2026. The goal is to show what the manufacturers themselves are telling investors — in their own cautious, legal-team-approved language — about where GLP-1 pricing and competition are heading.
Novo Nordisk: The Pricing Admission
In its 2025 annual report, Novo Nordisk explicitly acknowledged that the U.S. GLP-1 cash-pay market had moved into a new pricing regime. The company cited the $349/month NovoCare Wegovy launch as a strategic response to "competitive dynamics and patient affordability considerations." Buried in the risk factors section, the filing notes that continued price compression is "probable" through 2026 and into 2027.
The filing also disclosed the expected financial impact of the Medicare negotiation. Because the negotiated Maximum Fair Price takes effect January 1, 2027, the 2026 fiscal year is the last full year at pre-negotiation commercial pricing. Novo's guidance factors in roughly mid-single-digit revenue compression in the U.S. GLP-1 category for 2027 and beyond, partially offset by volume growth under expanded Medicare coverage.
Eli Lilly: The Volume Story
Lilly's 2025 filings emphasize a different narrative: volume growth and capacity expansion rather than price pressure. The December 2025 Zepbound vial price cut — bringing starting-dose pricing to $299/month — was disclosed as a strategic response to both competitive dynamics and capacity-utilization goals at Lilly's new manufacturing facilities.
| Disclosure Category | Novo Nordisk | Eli Lilly |
|---|---|---|
| 2026 U.S. price outlook | Compression probable | Continued pressure |
| Manufacturing expansion | Catalent integration | Indiana, N.C. facilities online |
| Medicare exposure (2027+) | Direct — semaglutide negotiated | Indirect — tirzepatide later cycle |
| Pipeline disclosures | CagriSema, oral Wegovy | Retatrutide, orforglipron |
Lilly's filings disclosed the ACHIEVE trial program for orforglipron (the oral small-molecule GLP-1) in detail, including the commercial launch timeline. The company's strategic framing is that a portfolio spanning injectable tirzepatide, oral orforglipron, and triple-agonist retatrutide will outpace Novo on both efficacy and dosing form.
Affordable direct-care marketplace — book a consultation with a licensed clinician for FDA-approved brand-name GLP-1 medications.
Brand-name · Insurance-friendly
Comprehensive GLP-1 weight management with licensed providers, labs, and home delivery.
Full-service GLP-1 program
Compounded semaglutide and tirzepatide programs with full medical consultation and ongoing provider support.
Compounded GLP-1 · Telehealth
Competitive Positioning Language
The formal language in SEC filings is legally cautious, but the competitive positioning bleeds through. Novo's filings reference "peer-manufactured products" and "generic and compounded alternatives" as competitive risks. Lilly's filings reference "innovator competition" and "emerging oral and multi-receptor options."
Neither company's filings treat compounded GLP-1s as a long-term competitive threat. Both treat them as a transitional issue tied to the resolved shortage. The narrative in both filings is consistent with the enforcement actions and settlements that have occurred: compounding was a supply-era phenomenon, and the commercial market is now between the two brand-name manufacturers and emerging patent-protected innovators.
What the Filings Don't Say
Both Novo and Lilly expect continued U.S. price compression through 2027, meaningful Medicare exposure starting in 2027, and a pipeline shift toward oral and multi-receptor products. None of this is secret — it's in their 10-Ks and investor calls.
What the filings don't commit to is an exact bottom. Neither company will say in writing how low they expect cash-pay prices to go, because any specific number is material non-public information that could move markets. The generic framing — "continued pressure," "compression probable," "competitive dynamics" — is legalese for an honest answer.
For readers who want to track the competitive trajectory quarter-by-quarter, the two most useful primary sources are Novo Nordisk's quarterly company announcements (filed with the Danish Financial Supervisory Authority and mirrored on SEC-equivalent disclosures) and Eli Lilly's 10-Q filings with the U.S. SEC. Both are freely available. For our related analysis, see our 2026 Novo vs. Lilly revenue forecast and review of the orforglipron ACHIEVE trials.
Sources
- Novo Nordisk. Form 20-F annual report, 2025 filing. www.sec.gov
- Eli Lilly and Company. Form 10-K annual report, 2025 filing. www.sec.gov
- Eli Lilly. Q4 2025 earnings release and conference call transcript. investor.lilly.com
- Novo Nordisk. Q4 2025 company announcement. www.novonordisk.com
- CMS. Medicare Drug Price Negotiation Program timeline documentation. www.cms.gov
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.